A Study of DM002 in Patients With Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling new participants at a higher dose of study drug. There will be up to six or more dose levels of study drug tested (called cohorts). Which dose you receive will depend on how many participants have taken part in the study before you. The purpose of Part 1 of the study is to evaluate the safety of the study drug at different dose levels, to understand what your body does to the study drug, and to find the best dose of study drug in people who have advanced solid tumor cancers. In Part 2, participants will receive the best dose level that was determined in Part 1 of the study. The purpose of Part 2 of the study is to evaluate the safety of the study drug at the dose level determined in Part 1, to understand what your body does to the study drug, and to see how your cancer responds to the study drug. Participants will: Participants will have 17 or more visits to the study centre. This study has a screening phase of up to 28 days , and a treatment phase with cycles of 21 days each. Participants will also have an End of Treatment (EOT) visit 21 days after the final study drug treatment, and a Follow-up visit 30 days after the EOT visit . Participants will be contacted by telephone every 3 months after the Follow-up visit to check on the wellbeing and record any new anticancer therapy they may have started.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Musisz rozumieć i chcieć podpisać zgodę na udział w badaniu.
- •Masz ukończone 18 lat.
- •Twój ogólny stan zdrowia pozwala na udział w badaniu (stan sprawności ECOG 0, 1 lub 2).
- •Przewidywana długość życia wynosi co najmniej 3 miesiące.
- •Twoje wyniki badań krwi spełniają określone normy (np. liczba białych i czerwonych krwinek, płytki krwi).
- •Twoje wyniki badań nerek i wątroby są w dopuszczalnych granicach.
- •Twoja choroba jest możliwa do zmierzenia zgodnie ze standardowymi wytycznymi.
- •Musisz dostarczyć próbkę tkanki guza z ostatnich 3 lat lub zgodzić się na biopsję, jeśli to bezpieczne.
✗ Disqualifies
- •Masz inną aktywną chorobę nowotworową, która rozpoczęła się w ciągu ostatnich 5 lat (z pewnymi wyjątkami).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (5)
University of Oklahoma Health Sciences Center
Oklahoma City, United States
The University of Texas, MD Anderson Cancer Center
Houston, United States
Scientia Clinical Research
Randwick, Australia
Cancer Care Wollongong
Wollongong, Australia
Southern Oncology Clinical Research Unit
Adelaide, Australia
Trial contact
Kathleen Moore, Doctor
Siqing Fu
Joe Wei, Doctor
UDIT NINDRA
Kichenadasse Ganessan, Doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.